CHRISTMAS disease is a hamorrhagic state mainly affecting males, which was not distinguished from hemophilia until I952, when it was shown by Aggeler, White, Glendening, Page, Leake and Bates (1952) and Biggs, Douglas, Macfarlane, Dacie, Pitney, Merskey and O'Brien (I952) that the two conditions were due to fundamentally different defects in the blood-clotting mechanism. To appreciate the significance of the distinction it is necessary to understand the nature of the prothrombin-converting system of the blood, on which normal coagulation depends. In normal blood most of the prothrombin disappears during clotting because it is converted to thrombin, which is subsequently inactivated by antithrombin. Consequently serum, examined one hour after normal blood has clotted in a glass tube, contains very little prothrombin. In both hamophilia and Christmas'disease serum examined in this way by the ' prothrombin consumption test' is found to contain large amounts of prothrombin, demonstrating a failure of the prothrombin-converting mechanism. In severe cases 'of either condition the coagulation time in glass tubes is also prolonged. The defects in the two conditions are thus far the same, and distinction can only be achieved by tests which reveal the prothrombinconverting system in greater detail. These have shown that the two diseases are caused by the lack of two different components required for the formation of a prothrombin activator in the blood (Biggs, Douglas and Macfarlane, I953) . Accurate diagnosis and the development of specific assay procedures for these two components which form the basis of modern therapy depend on an understanding of this system.
The factors concerned in the normal formation of prothrombin activator can be studied by the ' thromboplastin generation test ' devised by Biggs and Douglas (I953). It was found (Biggs, Douglas and Macfarlane, I953) that a mixture of normal plasma treated with AI(OH)3, normal serum, platelets and CaCl2 produces a substance which will greatly accelerate the clotting of plasma (substrate) in the presence of CaCl2. The AI(OH)3-treated plasma does not contain prothrombin because this is removed by the Al(OH)3 treatment.
Neither is there any appreciable amount of prothrombin in the normal serum. Thus the greatly accelerated clotting of the substrate cannot be due to thrombin, and must be due to rapid conversion of the prothrombin which it contains. The test, which is now usually carried out replacing platelets by some form of phospholipid, gives a direct record of ability to form a prothrombinconverting substance. It Table 2 ). This might be caused by an excess of female carriers among the daughters of Christmas disease carriers or due 
Symptoms of Christmas Disease
The symptoms of Christmas disease are exactly the same as those of haemophilia. The severely affected patient has multiple episodes of hamarthrosis with residual joint deformity, massive haematomata which often affect muscles as well as various other episodes of bleeding, including hamaturia, epistaxis, gastrointestinal bleeding and retroperitoneal bleeding. The mildly affected patient bleeds excessively only following trauma and in the majority of patients the disease is disclosed by serious bleeding after accidents, dental extraction or some other operative procedure. In our experience the mildly affected patient usually bleeds for three to 14 days after dental extraction and the bleeding is not controlled by pressure or suturing. This history distinguishes the type of bleeding from that of the common variety associated with mild capillary defects where bleeding is almost always stopped by pressure or suturing.
The Assay of Christmas Factor
On the theory that Christmas disease is a deficiency state caused by a lack of factor IX, therapy depends on the production and use of factor IX in a concentrated form. To achieve this it is imperative to have some more or less reliable method for the assay of factor IX which will not be affected seriously by any other irrelevant substance.
The preliminary discussion on the theory of blood coagulation mentioned a number of crude tests of clotting function and gave a complicated hypothesis of the interactions of the various factors concerned. This theory is pieced together from different fragments of more or less indirect evidence derived from empirical clotting tests. To devise a method of assay of an individual factor based on this unsure theoretical foundation is by no means easy. The normal action of a factor is usually defined by the effects of its lack in a particular class of patient and quantitative tests are therefore usually based on the ability of a sample to correct the clotting defect in a patient said to have the abnormality. In practice the assay of Christmas factor is carried out by making mixtures of a Christmas disease sample with the sample to be tested and assessing the degree of correction by one of the empirical tests using some standard of normality.
There To prepare concentrated material from whole blood is very wasteful unless the other plasma fractions can be used. We thought of making Christmas factor from animal blood, but two considerations made us discard this plan. In the first place, severely affected patients with Christmas disease are much more infrequent than those with haemophilia and it was thought that a sufficient supply might be obtained from human blood. The second consideration was that a fraction rich in Christmas factor activity is derived from a current large-scale human-plasma fractionation process. cases by Biggs and others (I96I). We can now add experience with five more patients. One of these had a major surgical operation, four had dental extractions and one was treated mainly because he was the type case of Christmas disease and it was naturally of interest to be certain that the material was effective in his case.
Case i.-H., aged 56. The patient was a severely affected bleeder with multiple joint deformity and a blood level of Christmas factor of o %. He had suffered for many years from bleeding heemorrhoids; these had been treated unsuccessfully by injection on many occasions and for the last two years he was becoming more and more incapacitated by chronic aneemia and required many transfusions. The patient was treated with a 14-day course of concentrated Christmas factor. On the fifth post-operative day two teeth were extracted at the patient's own request because he was so astonished at his freedom from bleeding and was anxious to take advantage of the opportunity to dispose of two troublesome teeth. The post-operative course was uneventful. The levels of Christmas factor (factor IX) and prothrombin in his blood are shown in Fig. 3 . Case 2.-C., aged 35, was a relatively mildly affected patient who had nevertheless bled excessively in the past following dental extractiqn. Despite daily plasma transfusion he had bled intermittently for nearly three group.bmj.com on August 14, 2017 -Published by http://pmj.bmj.com/ Downloaded from weeks following the extraction of seven teeth and required the transfusion of 7 pints of whole blood. He was given an eight-day course of Christmas factor concentrate and two teeth were removed entirely without bleeding.
Case 3.-F., aged 41, was a severely affected patient with no detectable Christmas factor in his blood and with multiple previous episodes of hemarthrosis. He had a total clearance of the remaining five teeth and stumps at one operation and was given nine daily injections of Christmas factor. The sockets were completely healed in I2 days. A record of his response to treatment is shown in Fig. 4 .
Case 4.-F., 41 -year-old patient who was clinically severely affected with disabled joints. The blood level of Christmas factor was 2%. He had an eight-day course of Christmas factor concentrate and remaining eight teeth and four roots were removed at one operation. There was no bleeding.
Case 5.-Stephen Christmas, age I5. The patient was admitted to hospital with an acute hemarthrosis of the left knee. He was given two injections of Christmas factor and the knee improved rapidly. Later he was again admitted with haemarthrosis and on this occasion was given doses of i,ooo ml. of plasma. The blood levels of Christmas factor after the concentrated material are shown in the chart in doubt that the concentrated material is effective in the control of traumatic bleeding even in the most severely-affected patients.
Some of the features of the treatment of these patients are of interest. The relation of the dose of material given and the response of the patient in terms of rise in plasma level of Christmas factor for six patients are given in Tables 3 and 4 . The result The expected rise in Christmas factor for a patient of this weight given dose volumes Of 2-400 ml. would vary from 25 to 27% per i,ooo ml. The average observed rise (12.2%/I,OOO ml.) is about 47% of this expected value.
for the first case of Biggs and others is omitted because the assay method had not been stabilized at the time that he was treated, and much technical difficulty was experienced in obtaining blood samples from an unco-operative small child whose arm had been amputated. The results with this first case were of the same general pattern as the others. From Table 3 it will be seen that the rise in the level of Christmas factor for case i was less than would be expected from the size of the dose given. In Table 3 the results of one case are given in detail. In Table 4 the average observed!rise in the level of Christmas factor per i,ooo ml. equivalent of the dose for five other patients is compared with the expected rise calculated for the size of the patient. It will be seen that in all five cases the observed rise is only a small proportion of that expected. This discrepancy might be due The concentrate used to treat these patients certainly contains large amounts of prothrombin and probably also factors VII and X. In liver disease some or all of these factors are much reduced, and if operation were proposed for a patient it seems very probable that this material would reduce hamorrhage. For natural deficiencies of factors VII and X also it would be reasonable to suppose that this material would be effective. Larrieu, Caen, Soulier and Bernard (1955) , have used a similar concentrate to treat the hmemostatic defect of liver disease with good results.
Conclusion
The properties ascribed to Factor IX might be, in some way, merely an aspect of Factor VIII when viewed under artificial conditions.
The findings described here are confirmatory evidence that Factor IX is a physiological entity. The preparation of human plasma fractions with high Factor IX activity was made possible by the use of assay methods based on the thromboplastin generation test, and the theory of a multifactorial system required for the normal formation of a prothrombin activator. Preparations which had high activity when tested in vitro by these methods have given excellent results when given intravenously in cases of severe Christmas disease undergoing surgery, and little doubt can now remain that Factor IX is a distinct and necessary component of the normal clotting mechanism.
